Natural history and genotype-phenotype correlations in 72 individuals with SATB2-associated syndrome.

Mark McIntosh,'s picture
PubMed URL: 
http://www.ncbi.nlm.nih.gov/pubmed/29436146
Author: 
Chung WK
Author List: 
Zarate YA
Smith-Hicks CL
Greene C
Abbott MA
Siu VM
Calhoun ARUL
Pandya A
Li C
Sellars EA
Kaylor J
Bosanko K
Kalsner L
Basinger A
Slavotinek AM
Perry H
Saenz M
Szybowska M
Wilson LC
Kumar A
Brain C
Balasubramanian M
Dubbs H
Ortiz-Gonzalez XR
Zackai E
Stein Q
Powell CM
Schrier Vergano S
Britt A
Sun A
Smith W
Bebin EM
Picker J
Kirby A
Pinz H
Bombei H
Mahida S
Cohen JS
Fatemi A
Vernon HJ
McClellan R
Fleming LR
Knyszek B
Steinraths M
Velasco Gonzalez C
Beck AE
Golden-Grant KL
Egense A
Parikh A
Raimondi C
Angle B
Allen W
Schott S
Algrabli A
Robin NH
Ray JW
Everman DB
Gambello MJ
Chung WK
Journal: 
Am J Med Genet A
PubMed ID: 
29436146
Pagination: 
925-935
Volume: 
176
Issue: 
4
Abstract: 
SATB2-associated syndrome (SAS) is an autosomal dominant disorder characterized by significant neurodevelopmental disabilities with limited to absent speech, behavioral issues, and craniofacial anomalies. Previous studies have largely been restricted to case reports and small series without in-depth phenotypic characterization or genotype-phenotype correlations. Seventy two study participants were identified as part of the SAS clinical registry. Individuals with a molecularly confirmed diagnosis of SAS were referred after clinical diagnostic testing. In this series we present the most comprehensive phenotypic and genotypic characterization of SAS to date, including prevalence of each clinical feature, neurodevelopmental milestones, and when available, patient management. We confirm that the most distinctive features are neurodevelopmental delay with invariably severely limited speech, abnormalities of the palate (cleft or high-arched), dental anomalies (crowding, macrodontia, abnormal shape), and behavioral issues with or without bone or brain anomalies. This comprehensive clinical characterization will help clinicians with the diagnosis, counseling and management of SAS and help provide families with anticipatory guidance.
Published Date: 
April, 2018

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.

Learn more.

Appointments & Referrals

Event Calendar

FIND A SPECIALIST

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.

 

Resource Finder

 

A free resource that provides access to information and support for individuals and families living with developmental disabilities.